Imagen de Portada
Código QR

Noradrenaline reduces ischemia-induced arrhythmia in anesthetized rats: involvement of alpha1-adrenoceptors and mitochondrial K ATP channels.

INTRODUCTION: We have evaluated the part played by the mitochondrial ATP-sensitive potassium (mK(ATP)) channels on effect of alpha(1)-adrenoceptor activation by noradrenaline in ischemia-induced ventricular arrhythmia. METHODS AND RESULTS: Anesthetized rats were subjected to 25 minutes of regional i...

Descripción completa

Publicado en:Journal of Cardiovascular Electrophysiology Vol. 19; no. 3; pp. 309 - 316
Autores principales: Imani A, Faghihi M, Sadr SS, Keshavarz M, Niaraki SS
Formato: Journal Article
Publicado: Wiley-Blackwell Mar2008
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105790696&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105790696
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10453873
        GSB
      jtl: Journal of Cardiovascular Electrophysiology
      issn: 10453873
      maglogo: Y
    pubinfo:
      dt: Mar2008
      vid: 19
      iid: 3
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        105790696
        2009988450
        NLM18070031
        105790696
      ppf: 309
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Noradrenaline reduces ischemia-induced arrhythmia in anesthetized rats: involvement of alpha1-adrenoceptors and mitochondrial K ATP channels.
      aug:
        au:
          Imani A
          Faghihi M
          Sadr SS
          Keshavarz M
          Niaraki SS
        affil: Department of Physiology, School of Medicine, Medical Sciences/University of Tehran, Tehran, IR Iran.
      sug:
        subj:
          Myocardial Ischemia Metabolism
          Norepinephrine Administration and Dosage
          Potassium Metabolism
          Receptors, Cell Surface Metabolism
          Receptors, Cell Surface
          Tachycardia, Ventricular Metabolism
          Adrenergic alpha-Agonists Administration and Dosage
          Animals
          Male
          Myocardial Ischemia Complications
          Myocardial Ischemia Drug Therapy
          Rats
          Tachycardia, Ventricular Drug Therapy
          Tachycardia, Ventricular Etiology
          Treatment Outcomes
          Male
      ab: INTRODUCTION: We have evaluated the part played by the mitochondrial ATP-sensitive potassium (mK(ATP)) channels on effect of alpha(1)-adrenoceptor activation by noradrenaline in ischemia-induced ventricular arrhythmia. METHODS AND RESULTS: Anesthetized rats were subjected to 25 minutes of regional ischemia, and infarct size (IS) and ischemia-induced ventricular arrhythmia were measured. Group I served as saline control with ischemia (n = 9). In group II (n = 9), the ischemic period was preceded by three short episodes of ischemia, followed by reperfusion. In group III, noradrenaline (2 microg/kg, IV, n = 9) was injected prior to ischemia. In group IV, an alpha(1)-adrenoceptor blocker (prazosin, 0.5 mg/kg, IV, n = 6) was administrated prior to noradrenaline injection. In Groups V and VI, rats received a specific mitochondrial K(ATP) channel inhibitor [5-hydroxydecanoic acid (5-HD), 10 mg/kg, IV, n = 6] prior to or after noradrenaline injection. Ischemic preconditioning (IPC) and noradrenaline markedly reduced incidences of ventricular fibrillation (VF) (0%, 0% vs. 55.5% in control, P < 0.05) and ventricular tachycardia (VT) (11%, 44.5% vs. 100% in control, P < 0.001 and P < 0.05), duration of VF + VT (3 +/- 1 seconds, 4.7 +/- 2.1 seconds vs. 52.9 +/- 6 seconds in control, P < 0.001), number of VF + VT episodes (1.7 +/- 1.7, 5.75 +/- 2.4 vs. 60.5 +/- 8 in control, P < 0.001), severity of arrhythmias (0.3 +/- 0.3, 1.7 +/- 0.5 vs. 3.9 +/- 0.3 in control rats, P < 0.001 and P < 0.01), and IS (13.6 +/- 1.8%, 18.2 +/- 1.5% vs. 49.6 +/- 2.4% in control, P < 0.001). Administration of prazosin or 5-HD prior to or after noradrenaline injection intensified incidences of VF (66.6%, 66.6% and 50%, P < 0.05) and VT (100%, 100%, and 100%, P < 0.05), duration of VF + VT episodes (70.2 +/- 10.5 seconds, 69.8 +/- 6.75 seconds, and 60.8 +/- 14.9 seconds, P < 0.001), number of VF + VT episodes (56 +/- 16.4, 67 +/- 11, and 45 +/- 3.5, P < 0.01, P < 0.001, and P < 0.05), severity of arrhythmias(3.8 +/- 0.3, 4 +/- 0.5, and 3.7 +/- 0.2, P < 0.01, P < 0.05, and P < 0.01), and IS (45.5 +/- 3%, 46.8 +/- 3.4%, and 43 +/- 2.5%, respectively, P < 0.001) compared with the noradrenaline-treated group. CONCLUSION: Prazosin or 5-HD treatment eliminated the beneficial effects of noradrenaline on arrhythmogenesis and infarct size.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N